These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 12855616)

  • 21. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
    Orlando L; Cardillo A; Ghisini R; Rocca A; Balduzzi A; Torrisi R; Peruzzotti G; Goldhirsch A; Pietri E; Colleoni M
    BMC Cancer; 2006 Sep; 6():225. PubMed ID: 16978400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.
    Modi S; Stopeck A; Linden H; Solit D; Chandarlapaty S; Rosen N; D'Andrea G; Dickler M; Moynahan ME; Sugarman S; Ma W; Patil S; Norton L; Hannah AL; Hudis C
    Clin Cancer Res; 2011 Aug; 17(15):5132-9. PubMed ID: 21558407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
    Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J
    Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer.
    Theodoulou M; Batist G; Campos S; Winer E; Welles L; Hudis C
    Clin Breast Cancer; 2009 May; 9(2):101-7. PubMed ID: 19433391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.
    Perez EA; Suman VJ; Rowland KM; Ingle JN; Salim M; Loprinzi CL; Flynn PJ; Mailliard JA; Kardinal CG; Krook JE; Thrower AR; Visscher DW; Jenkins RB
    Clin Breast Cancer; 2005 Dec; 6(5):425-32. PubMed ID: 16381626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.
    Krop IE; Beeram M; Modi S; Jones SF; Holden SN; Yu W; Girish S; Tibbitts J; Yi JH; Sliwkowski MX; Jacobson F; Lutzker SG; Burris HA
    J Clin Oncol; 2010 Jun; 28(16):2698-704. PubMed ID: 20421541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series.
    Ardavanis A; Tryfonopoulos D; Orfanos G; Karamouzis M; Scorilas A; Alexopoulos A; Rigatos G
    Onkologie; 2005 Nov; 28(11):558-64. PubMed ID: 16249641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant weekly paclitaxel with and without trastuzumab in locally advanced or metastatic breast cancer.
    Horiguchi J; Oyama T; Koibuchi Y; Yokoe T; Takata D; Ikeda F; Nagaoka H; Rokutanda N; Nagaoka R; Ishikawa Y; Odawara H; Kikuchi M; Sato A; Iino Y; Takeyoshi I
    Anticancer Res; 2009 Feb; 29(2):517-24. PubMed ID: 19331197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy.
    Acevedo-Gadea C; Hatzis C; Chung G; Fishbach N; Lezon-Geyda K; Zelterman D; DiGiovanna MP; Harris L; Abu-Khalaf MM
    Breast Cancer Res Treat; 2015 Feb; 150(1):157-67. PubMed ID: 25687356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel.
    Leyland-Jones B; Gelmon K; Ayoub JP; Arnold A; Verma S; Dias R; Ghahramani P
    J Clin Oncol; 2003 Nov; 21(21):3965-71. PubMed ID: 14507946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
    Schaller G; Fuchs I; Gonsch T; Weber J; Kleine-Tebbe A; Klare P; Hindenburg HJ; Lakner V; Hinke A; Bangemann N
    J Clin Oncol; 2007 Aug; 25(22):3246-50. PubMed ID: 17577021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer.
    Kubo M; Morisaki T; Kuroki H; Tasaki A; Yamanaka N; Matsumoto K; Nakamura K; Onishi H; Baba E; Katano M
    Anticancer Res; 2003; 23(6a):4443-9. PubMed ID: 14666732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.
    Yardley DA; Raefsky E; Castillo R; Lahiry A; Locicero R; Thompson D; Shastry M; Burris HA; Hainsworth JD
    Clin Breast Cancer; 2011 Oct; 11(5):297-305. PubMed ID: 21729666
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
    Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
    Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer.
    Montemurro F; Choa G; Faggiuolo R; Donadio M; Minischetti M; Durando A; Capaldi A; Vietti-Ramus G; Alabiso O; Aglietta M
    Oncology; 2004; 66(1):38-45. PubMed ID: 15031597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study.
    Janku F; Pribylova O; Zimovjanova M; Pazdrova G; Safanda M; Zemanova M; Petruzelka L
    Bull Cancer; 2004 Oct; 91(10):E279-83. PubMed ID: 15582895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience.
    Horiguchi J; Oyama T; Takata D; Rokutanda N; Nagaoka R; Odawara H; Tokiniwa H; Tozuka K; Kikuchi M; Sato A; Takeyoshi I
    Anticancer Res; 2011 Sep; 31(9):3041-6. PubMed ID: 21868556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
    Shak S
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial.
    De Maio E; Pacilio C; Gravina A; Morabito A; Di Rella F; Labonia V; Landi G; Nuzzo F; Rossi E; Silvestro P; Botti G; Di Bonito M; Curcio MP; Formichelli F; La Vecchia F; Staiano M; Maurea N; D'Aiuto G; D'Aiuto M; Thomas R; Signoriello G; Perrone F; de Matteis A
    BMC Cancer; 2007 Mar; 7():50. PubMed ID: 17374151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial.
    Tedesco KL; Thor AD; Johnson DH; Shyr Y; Blum KA; Goldstein LJ; Gradishar WJ; Nicholson BP; Merkel DE; Murrey D; Edgerton S; Sledge GW
    J Clin Oncol; 2004 Mar; 22(6):1071-7. PubMed ID: 15020608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.